Tumor lysis syndrome cost-effectiveness of therapy: Difference between revisions
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}} {{AE}} {{MJK}} | {{CMG}} {{AE}} {{MJK}} | ||
==Overview== | ==Overview== | ||
The cost of administration of a singe low dose (3 mg) of [[rasburicase]] for tumor lysis syndrome prevention in cancer patients is superior to the daily IV [[allopurinol]].<ref name="pmid22644973">{{cite journal| author=Patel S, Le A, Gascon S| title=Cost-effectiveness of rasburicase over i.v. allopurinol for treatment of tumor lysis syndrome. | journal=Am J Health Syst Pharm | year= 2012 | volume= 69 | issue= 12 | pages= 1015-6 | pmid=22644973 | doi=10.2146/ajhp110656 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22644973 }} </ref> | The cost-effectiveness of administration of a singe low dose (3 mg) of [[rasburicase]] for tumor lysis syndrome prevention in cancer patients is superior to the daily IV [[allopurinol]].<ref name="pmid22644973">{{cite journal| author=Patel S, Le A, Gascon S| title=Cost-effectiveness of rasburicase over i.v. allopurinol for treatment of tumor lysis syndrome. | journal=Am J Health Syst Pharm | year= 2012 | volume= 69 | issue= 12 | pages= 1015-6 | pmid=22644973 | doi=10.2146/ajhp110656 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22644973 }} </ref> | ||
==Cost-Effectiviness of Therapy== | ==Cost-Effectiviness of Therapy== | ||
The cost of administration of a singe low dose (3 mg) of [[rasburicase]] for tumor lysis syndrome prevention in cancer patients is superior to the daily IV [[allopurinol]].<ref name="pmid22644973">{{cite journal| author=Patel S, Le A, Gascon S| title=Cost-effectiveness of rasburicase over i.v. allopurinol for treatment of tumor lysis syndrome. | journal=Am J Health Syst Pharm | year= 2012 | volume= 69 | issue= 12 | pages= 1015-6 | pmid=22644973 | doi=10.2146/ajhp110656 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22644973 }} </ref> | The cost-effectiveness of administration of a singe low dose (3 mg) of [[rasburicase]] for tumor lysis syndrome prevention in cancer patients is superior to the daily IV [[allopurinol]].<ref name="pmid22644973">{{cite journal| author=Patel S, Le A, Gascon S| title=Cost-effectiveness of rasburicase over i.v. allopurinol for treatment of tumor lysis syndrome. | journal=Am J Health Syst Pharm | year= 2012 | volume= 69 | issue= 12 | pages= 1015-6 | pmid=22644973 | doi=10.2146/ajhp110656 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22644973 }} </ref> | ||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
Revision as of 17:51, 23 September 2015
|
Tumor lysis syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Tumor lysis syndrome cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Tumor lysis syndrome cost-effectiveness of therapy |
|
Tumor lysis syndrome cost-effectiveness of therapy in the news |
|
Risk calculators and risk factors for Tumor lysis syndrome cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2]
Overview
The cost-effectiveness of administration of a singe low dose (3 mg) of rasburicase for tumor lysis syndrome prevention in cancer patients is superior to the daily IV allopurinol.[1]
Cost-Effectiviness of Therapy
The cost-effectiveness of administration of a singe low dose (3 mg) of rasburicase for tumor lysis syndrome prevention in cancer patients is superior to the daily IV allopurinol.[1]
References
- ↑ 1.0 1.1 Patel S, Le A, Gascon S (2012). "Cost-effectiveness of rasburicase over i.v. allopurinol for treatment of tumor lysis syndrome". Am J Health Syst Pharm. 69 (12): 1015–6. doi:10.2146/ajhp110656. PMID 22644973.